Physicians disagree with acetaminophen restrictions
This article was originally published in The Tan Sheet
A large majority -- 82 percent -- of recently surveyed physicians does not agree that FDA should pull acetaminophen products off the market. HCD Research surveyed 589 physicians July 17-19 after a joint advisory panel recommended FDA remove prescription acetaminophen products from the market, but said OTC combo products could stay. It also advised the agency restrict the amount of acetaminophen in OTC tablets and lower the dose (1"Health News Daily" July 1, 2009). While 86 percent of the physicians said the panel's recommendation will not change whether they will continue prescribing acetaminophen Rx drugs or recommending OTC drugs for their patients, nearly a third -- 29 percent -- said they are more likely to discuss warnings and dosage instructions with patients who use acetaminophen products, Flemington, N.J.-based HCD said July 20
You may also be interested in...
A trio of newly finalized guidance documents from the US agency dated 25 September explain how the Accreditation Scheme for Conformity Assessment pilot will work, and what biocompatibility and safety standards will apply.
Approval of Alaway Preservative Free (ketotifen fumarate, 0.035) comes 15 months after FDA submitted a complete response letter to Bausch and the active ingredient developer, Eton Pharmaceuticals.
Unfounded expectation some firms have for FDA to protect their investments in preparing successful NDI notifications is part of industry’s overall interest in increased regulation of the market, says Steven Tave, Office of Dietary Supplement Programs director.